RNAC Relative Valuation
RNAC's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, RNAC is overvalued; if below, it's undervalued.
Historical Valuation
Cartesian Therapeutics Inc (RNAC) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.67. The fair price of Cartesian Therapeutics Inc (RNAC) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：6.93
Fair
-2.02
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Cartesian Therapeutics Inc. (RNAC) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is -1.29. The thresholds are as follows: Strongly Undervalued below -5.99, Undervalued between -5.99 and -3.64, Fairly Valued between 1.06 and -3.64, Overvalued between 1.06 and 3.41, and Strongly Overvalued above 3.41. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.42
EV/EBIT
Cartesian Therapeutics Inc. (RNAC) has a current EV/EBIT of -0.42. The 5-year average EV/EBIT is -3.53. The thresholds are as follows: Strongly Undervalued below -8.54, Undervalued between -8.54 and -6.03, Fairly Valued between -1.03 and -6.03, Overvalued between -1.03 and 1.48, and Strongly Overvalued above 1.48. The current Forward EV/EBIT of -0.42 falls within the Overvalued range.
363.90
PS
Cartesian Therapeutics Inc. (RNAC) has a current PS of 363.90. The 5-year average PS is 158.35. The thresholds are as follows: Strongly Undervalued below -232.70, Undervalued between -232.70 and -37.17, Fairly Valued between 353.87 and -37.17, Overvalued between 353.87 and 549.40, and Strongly Overvalued above 549.40. The current Forward PS of 363.90 falls within the Overvalued range.
0.00
P/OCF
Cartesian Therapeutics Inc. (RNAC) has a current P/OCF of 0.00. The 5-year average P/OCF is -3.25. The thresholds are as follows: Strongly Undervalued below -14.78, Undervalued between -14.78 and -9.01, Fairly Valued between 2.52 and -9.01, Overvalued between 2.52 and 8.29, and Strongly Overvalued above 8.29. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-2.15
P/FCF
Cartesian Therapeutics Inc. (RNAC) has a current P/FCF of -2.15. The 5-year average P/FCF is -9.00. The thresholds are as follows: Strongly Undervalued below -22.57, Undervalued between -22.57 and -15.78, Fairly Valued between -2.22 and -15.78, Overvalued between -2.22 and 4.56, and Strongly Overvalued above 4.56. The current Forward P/FCF of -2.15 falls within the Overvalued range.
Cartesian Therapeutics Inc (RNAC) has a current Price-to-Book (P/B) ratio of -4.82. Compared to its 3-year average P/B ratio of 81.88 , the current P/B ratio is approximately -105.89% higher. Relative to its 5-year average P/B ratio of 81.88, the current P/B ratio is about -105.89% higher. Cartesian Therapeutics Inc (RNAC) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -19.77%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -19.77% , the current FCF yield is about -100.00% lower.
-5.01
P/B
Median3y
81.88
Median5y
81.88
-39.84
FCF Yield
Median3y
-19.77
Median5y
-19.77
Competitors Valuation Multiple
The average P/S ratio for RNAC's competitors is 0.00, providing a benchmark for relative valuation. Cartesian Therapeutics Inc Corp (RNAC) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 16.80%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of RNAC decreased by 61.47% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -6.25K to -7.94K.
The secondary factor is the Revenue Growth, contributed 16.80%to the performance.
Overall, the performance of RNAC in the past 1 year is driven by Margin Expansion. Which is more sustainable.
People Also Watch
FAQ
Is Cartesian Therapeutics Inc (RNAC) currently overvalued or undervalued?
What is Cartesian Therapeutics Inc (RNAC) fair value?
How does RNAC's valuation metrics compare to the industry average?
What is the current P/B ratio for Cartesian Therapeutics Inc (RNAC) as of Dec 05 2025?
What is the current FCF Yield for Cartesian Therapeutics Inc (RNAC) as of Dec 05 2025?
What is the current Forward P/E ratio for Cartesian Therapeutics Inc (RNAC) as of Dec 05 2025?